Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled pha
about
Tapentadol for chronic musculoskeletal pain in adultsA Systematic Review of Dextrose Prolotherapy for Chronic Musculoskeletal PainTapentadol: Can It Kill Two Birds with One Stone without Breaking Windows?Systematic literature review and meta-analysis of the efficacy and safety of prescription opioids, including abuse-deterrent formulations, in non-cancer pain managementNeuropathic cancer pain: What we are dealing with? How to manage it?Cardiac Effects of Opioid TherapyMechanistic and functional differentiation of tapentadol and tramadolA Model-Based Meta-analysis to Compare Efficacy and Tolerability of Tramadol and Tapentadol for the Treatment of Chronic Non-Malignant Pain.Evaluation of blood pressure and heart rate in patients with hypertension who received tapentadol extended release for chronic pain: a post hoc, pooled data analysis.Tapentadol Prolonged Release for Chronic Pain: A Review of Clinical Trials and 5 Years of Routine Clinical Practice Data.The efficacy of duloxetine, non-steroidal anti-inflammatory drugs, and opioids in osteoarthritis: a systematic literature review and meta-analysis.Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended releaseDriving Ability in Patients with Severe Chronic Low Back or Osteoarthritis Knee Pain on Stable Treatment with Tapentadol Prolonged Release: A Multicenter, Open-label, Phase 3b Trial.Progressive change in joint degeneration in patients with knee or hip osteoarthritis treated with fentanyl in a randomized trial.Combining opioid and adrenergic mechanisms for chronic pain.Tapentadol in pain management: a μ-opioid receptor agonist and noradrenaline reuptake inhibitor.[Undesired side effects of tapentadol in comparison to oxycodone. A meta-analysis of randomized controlled comparative studies].μ-Opioid receptor activation and noradrenaline transport inhibition by tapentadol in rat single locus coeruleus neuronsTapentadol extended release in the management of peripheral diabetic neuropathic painA pooled analysis evaluating the efficacy and tolerability of tapentadol extended release for chronic, painful diabetic peripheral neuropathyTapentadol prolonged release for patients with multiple myeloma suffering from moderate-to-severe cancer pain due to bone disease.Lasting Prolonged-Release Tapentadol for Moderate/Severe Non-Cancer Musculoskeletal Chronic Pain.Effectiveness and safety of tapentadol prolonged release with tapentadol immediate release on-demand for the management of severe, chronic osteoarthritis-related knee pain: results of an open-label, phase 3b study.Tapentadol for Cancer Pain Management: A Narrative Review.Pain treatment in arthritis-related pain: beyond NSAIDs.Patient considerations in the use of tapentadol for moderate to severe pain.Validity and responsiveness of EuroQol-5 dimension (EQ-5D) versus Short Form-6 dimension (SF-6D) questionnaire in chronic pain.Effectiveness and tolerability of tapentadol prolonged release compared with prior opioid therapy for the management of severe, chronic osteoarthritis painOptions for treating postherpetic neuralgia in the medically complicated patient.Pharmacological agents currently in clinical trials for disorders in neurogastroenterology.Mitigating the risk of opioid abuse through a balanced undergraduate pain medicine curriculum.Patient therapeutic education: placing the patient at the centre of the WHO analgesic ladder.Opioid-induced constipation: challenges and therapeutic opportunities.Tapentadol extended-release for treatment of chronic pain: a review.The NSAID dilemma: managing osteoarthritis in high-risk patients.Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome.New treatment options for chronic constipation: mechanisms, efficacy and safety.Tapentadol for pain: a treatment evaluation.Tapentadol extended release: in adults with chronic pain.Fixed-dose combinations for emerging treatment of pain.
P2860
Q24187807-B61D2ACB-E0C7-4FA5-B22B-E325D7890A10Q26739953-B8233144-9A59-4FCC-8252-D71CB24A0FC2Q26740394-0939C800-D9A5-4CD2-B5A6-3C1EC3830F5AQ26853312-DCFF5528-4DBE-4A8D-9947-765366B47347Q26998945-7EF2B20D-C2AB-4BBD-BAD3-A5D74B614DE9Q28083959-713F30CD-7DA0-47A1-9618-0C53FDE4B38EQ28268772-F4680B3E-C50D-4FB3-ACC4-564A21C2B45DQ30487222-363781EF-EC8D-469A-AC65-C4F4A1F0242EQ30830216-969BF558-2284-4830-9302-9296ADB66CDEQ31128284-3D67C2C1-ED43-458B-A7A7-8554B9E30BD6Q33556721-50E74D8F-F756-4A7E-9A08-5DC507084625Q33775071-980B1F03-8ABC-4533-8A66-0D41DF5BF7D1Q33938745-5F9FA90F-4561-4A36-A860-EB5354C1B8B4Q33941683-C9EEA55D-83B4-48ED-A869-5A9C728B3D1EQ34434307-EBBB2A2D-BF06-4EB2-AFBD-75BF785E7DA5Q34628322-EFE137C5-FB72-46E0-90F0-9E7C686DC183Q34636179-12AEB86F-A7BE-4CA9-A3B5-8AAC5A52E953Q34939720-26AD3B16-5131-481A-A709-9DCBD48DD0F5Q34982228-104D5173-DA38-4A71-9848-4504A7A35D6DQ34990241-2D6084E0-A377-4E43-9A9E-0DB80C5361C3Q35605900-CC9EEF8B-B058-4424-BE72-67FC3079CD57Q35752535-DC856D74-1BA6-41F5-8715-466F44BDDE05Q36085061-8F0428EB-8E2B-4A49-9D51-E63670B9314CQ36248445-8C5A05D0-6CE8-4824-B0C4-CB863964C1B0Q36481613-DFD0A92D-B7FE-4024-9777-0374F50F6877Q36991981-2A69463E-111D-46FB-BCFC-805CBC0687F8Q37042212-EECF4E79-0B75-48D7-B2A3-421C4EEE6DC9Q37115472-B5C6A784-8A7F-471A-B932-D9FEA37DF1A9Q37120711-8640EE7F-38F5-47D8-9717-5687ACC70173Q37200907-AA503BAF-854B-4CA2-AE6A-34FA7665C46BQ37390742-C6433CDE-AE1F-4B05-8C4E-6037EBDD8F15Q37635222-FB140268-1EEA-4702-BF9B-47164EAA2C51Q37846099-F96605B2-26C7-4485-B305-F958260C973FQ37925605-2036192B-0522-43B8-8BF5-BCD21DFD28BFQ37949849-FADDDA07-7863-4705-A766-B5DF58739253Q37954521-E226A432-6487-48A3-80CF-71FC2FD48DE3Q37960501-B51267EE-C1B0-4BDC-9AB7-319E34A428D0Q37970786-9F7EA752-5AF7-49F3-8D50-89D0F7D91D09Q37982435-A459F3BA-BBBF-4C4F-BC1C-B72C1D77CE1AQ37993955-4DCBC737-9912-4C3A-B48A-54CA260BD46A
P2860
Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled pha
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Efficacy and safety of Tapenta ...... ebo- and active-controlled pha
@en
Efficacy and safety of Tapenta ...... ebo- and active-controlled pha
@nl
type
label
Efficacy and safety of Tapenta ...... ebo- and active-controlled pha
@en
Efficacy and safety of Tapenta ...... ebo- and active-controlled pha
@nl
prefLabel
Efficacy and safety of Tapenta ...... ebo- and active-controlled pha
@en
Efficacy and safety of Tapenta ...... ebo- and active-controlled pha
@nl
P2093
P2860
P921
P1476
Efficacy and safety of Tapenta ...... ebo- and active-controlled pha
@en
P2093
Achim Steup
Akiko Okamoto
Bernd Lange
Brigitte Kuperwasser
Ilse Van Hove
Juergen Haeussler
Kathy Kelly
Marc Afilalo
Mila S Etropolski
P2860
P304
P356
10.2165/11533440-000000000-00000
P577
2010-01-01T00:00:00Z